10-YEAR CARDIOVASCULAR RISK REDUCTION, EFFICACY AND SAFETY OF ALIROCUMAB AND EVOLOCUMAB, IN ADDITION TO MAXIMAL TOLERATED CHOLESTEROL LOWERING THERAPY: POST-COMMERCIALIZATION STUDY
2017
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI